Published: January 7, 2013
Tags: breach of contract, breach of fiduciary duty, deceptive trade practices, ethics, fraud, legal ethics, mass tort, negligence, referral fees, settlements, silicosis litigation
A number of recent lawsuits filed by plaintiffs allege that companies are falsely advertising their products as “all natural” or “100 percent” natural when they in fact contain synthetic ingredients or genetically modified organisms.
Federal law immunizes StubHub from a state lawsuit alleging that the online ticket company engaged in unfair or deceptive trade practices by scalping tickets, the North Carolina Court of Appeals has ruled in reversing a summary judgment.
After winning a $22 million medical malpractice verdict on behalf of a young man who went into the hospital complaining of neck pain and left paralyzed from the waist down, lawyers for the man won a $3.4 million verdict last month in a companion case against a doctor’s insurance company for not covering the malpractice award.
A judge has ordered the maker of Risperdal to pay $327 million in civil penalties to the state of South Carolina for its marketing of the antipsychotic drug.
Consumers must show detrimental reliance in order to hold a drug manufacturer liable for misleading statements in its marketing of hormone replacement therapy drugs, West Virginia’s highest court has ruled.
Drug maker AstraZeneca can’t be sued for allegedly falsely marketing Nexium as “new” and “better” than Prilosec even though the two drugs were very similar, because the FDA approved its labeling, the Arkansas Supreme Court has ruled.
A Dallas jury has ordered Texas-based Advocare International to pay $1.8 million for unfairly ending its agreement with a couple who had built a lucrative distributorship selling the company’s nutritional supplements and wellness products.